We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00005300
Recruitment Status : Completed
First Posted : May 26, 2000
Last Update Posted : April 14, 2016
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)

Brief Summary:
To continue to follow the newborn cohort and the over-35 years of age cohort from the Cooperative Study of Sickle Cell Disease (CSSCD), a study of the natural history of sickle cell disease.

Condition or disease
Anemia, Sickle Cell Blood Disease

Detailed Description:


The Cooperative Study of Sickle Cell Disease was initiated in 1977 to determine the natural history of sickle cell disease from birth to death in order to identify those factors contributing to the morbidity and mortality of the disease. Patients in the study had been followed previously in CSSCD.

Follow-up of the newborn cohort provided data demonstrating that life-threatening septicemia can occur as early as four months of age, and that the incidence of septicemia in children with sickle cell disease is higher than previously reported. Serial measurements of pocked or vesiculated red blood cells determined the onset of splenic dysfunction. The loss of splenic function has been characterized by genotype and the observed patterns of loss of splenic function were different developmentally depending on the sickle hemoglobinopathy syndrome.

Growth retardation, which becomes obvious around seven years of age, has no relationship to reported family income. Prophylactic oral penicillin can decrease morbidity and mortality associate with pneumococcal septicemia. The newborn infant cohort was unique in determining issues related to the natural history of the disease because the information was prospective and has been captured in the database. The complex database permitted an opportunity to determine outcomes, risk factors, and the application of the severity index to determine the spectrum of severity.

Follow-up of the over-35 cohort is important because it was not so long ago that it was estimated that 50 percent of patients with sickle cell anemia in the United States died before their twentieth birthday. However, data accumulated over the past eight years by the CSSCD demonstrates that this is incorrect. Survival beyond the age of forty suggests that surviving patients are somehow different from other patients with a high mortality in the earlier years. Therefore, they constitute a cohort of special interest, and the reasons for prolonged survival in this disease remain to be well documented prospectively. Technology is now available to identify genetic differences which may influence survival.

Based on the findings of the earlier CSSCD, the Blood Diseases and Resources Advisory Committee Red Cell Working Group recommended this initiative which was approved by the May 1987 National Heart, Lung, and Blood Advisory Council. The Request for Proposals was released in February 1988 and awards made in October 1988.


Follow-up of the newborn cohort continued in order to better understand the severity, onset of early organ damage, and risk factors. Patients were given an entry evaluation consisting of interim history, complete physical examination, complete blood count, urinalysis, blood drawn for haplotype determination and for the serum bank, magnetic resonance imaging of the brain, pulmonary function tests with arterial blood gas, and psychomotor tests. Patients had interim assessments at six months and annual assessments as well as an exit assessment in the fourth or fifth years. The exit assessment was the same as the entry assessment.

Follow-up of the over-35 cohort continued in order to better understand factors that contribute to longevity. Entry evaluation consisted of interim history, complete physical examination, complete blood count, urinalysis, blood drawn for haplotype determination and for the serum bank, cardiac MUGA, and renal and pulmonary function tests. Follow-up was yearly with an exit evaluation in the fourth or fifth years.

Layout table for study information
Study Type : Observational
Study Start Date : October 1988
Study Completion Date : June 1995

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 100 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
No eligibility criteria
Study Data/Documents: Individual Participant Data Set  This link exits the ClinicalTrials.gov site
Identifier: CSSCD
NHLBI provides controlled access to IPD through BioLINCC. Access requires registration, evidence of local IRB approval or certification of exemption from IRB review, and completion of a data use agreement.

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00005300    
Other Study ID Numbers: 3001
First Posted: May 26, 2000    Key Record Dates
Last Update Posted: April 14, 2016
Last Verified: May 2000
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Hematologic Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Genetic Diseases, Inborn